AstraZeneca (AZN) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $242.63B | Exchange | NYSE |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | GB | CEO | Pascal Claude Roland Soriot |
| IPO Date | 1993-05-12 | CAGR | 6.12% |
| Employees | 96,100 | Website | www.astrazeneca.com |
| Div. Yield | 4.18% | Payout Ratio | 47% |
| Buy Back Yield | 0.45% | Total Yield | 4.63% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $283.30B | P/E | 16.9 | Forward P/E | 13.51 | PEG | 9.41 |
| P/S | 1.9 | P/B | 2.29 | P/CF | 8.46 | P/FCF | 13.78 |
| Sales | $61.18B | Sales 1Y | 8.27% | Sales 3Y | 37.52% | Sales 5Y | 107.18% |
| EPS | $9.26 | EPS 1Y | 25.42% | EPS 3Y | 68.18% | EPS 5Y | 132.06% |
| Sales QoQ | -0.61% | EPS QoQ | -19.29% | Sales QoQ Avg | 1.28% | EPS QoQ Avg | 2.09% |
| Gross Margin | 79.27% | Operating Margin | 22.69% | Profit Margin | 17.02% | ROCE | 16.41% |
| ROA | 9% | ROE | 22% | Altman Z Score | 3.25 | Piotroski Score | 7 |
| Current Ratio | 0.89 | Quick Ratio | 0.67 | Cash Ratio | 0.16 | Op. CF Ratio | 0.09 |
| Debt/Equity | 0.64 | Debt/Assets | 0.28 | Lt Debt/Equity | 0.52 | Lt Debt/Cap. | 0.32 |
| Intrst Cov. | 7.97 | Inventory Turnover | 1.82 | Asset Turnover | 0.53 | Receivables Turnover | 3.81 |
| Enterprise Value | $283.30B | P/E Ratio | 16.9 |
| Forward P/E | 13.51 | PEG Ratio | 9.41 |
| P/S Ratio | 1.9 | P/B Ratio | 2.29 |
| P/CF Ratio | 8.46 | P/FCF Ratio | 13.78 |
| EPS | $9.26 | EPS Growth 1Y | 25.42% |
| EPS Growth 3Y | 68.18% | EPS Growth 5Y | 132.06% |
| Revenue Growth 1Y | 8.27% | Gross Margin | 0.79% |
| Operating Margin | 0.23% | Profit Margin | 0.17% |
| ROE | 0.22% | ROA | 0.09% |
| ROCE | 0.16% | Current Ratio | 0.89 |
| Quick Ratio | 0.67 | Cash Ratio | 0.16 |
| Debt/Equity | 0.64 | Interest Coverage | 7.97 |
| Altman Z Score | 3.25 | Piotroski Score | 7 |
AstraZeneca (AZN) valuation & financials
AstraZeneca (AZN) has a market capitalization of $242.63B and trades at a price-to-earnings ratio of 16.9. It operates in the Healthcare sector (Drug Manufacturers - General).
AstraZeneca's revenue grew +8.3% over the last year.
AstraZeneca's next earnings report is scheduled for October 30, 2026 before market open; analysts estimate EPS of $2.64. Check the earnings calendar to see all companies reporting this week.
AstraZeneca (AZN) — frequently asked questions
When does AstraZeneca (AZN) report earnings next?
AstraZeneca is expected to report earnings on October 30, 2026 before market open. Analysts estimate EPS of $2.64.
What is AstraZeneca's market cap?
AstraZeneca (AZN) has a market capitalization of $242.63B.
What is AZN's P/E ratio?
AstraZeneca trades at a price-to-earnings ratio of 16.9, with trailing twelve-month EPS of $9.26.
How fast is AstraZeneca growing?
AstraZeneca's revenue grew +8.3% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)